Novo Nordisk rebounds
New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.
In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...
Insurance companies generally cover Ozempic and Wegovy when it is prescribed for Type 2 diabetes. However, when the drugs are ...
Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...
Novo Nordisk launched "My Ozempic® Era" today, a national campaign which spotlights the longstanding Ozempic® patient ...
Get key updates on stock ratings this week, from Intel's leadership-driven upgrade to Apple's tariff challenges.
Wegovy contains the same main ingredient as Ozempic, semaglutide, and is FDA-approved for weight loss in people with obesity or who are overweight with at least one weight-related condition. It is ...
Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results